SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on May 5, 2017. The report details a corporate governance action involving a reverse stock split and a reduction in authorized shares. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on capital structure changes rather than financial performance.
Material Changes
- Reverse Stock Split: The Company effected a one-for-ten reverse split of its outstanding common stock. Each ten shares issued and outstanding were reclassified into one share.
- Authorized Share Reduction: The number of authorized shares was reduced to 50 million for common stock and 10 million for preferred stock.
- Effective Date: The changes became effective at 7:00 a.m. Eastern Standard Time on May 5, 2017.
- Par Value: The par value remains $0.0001 per share.
Guidance, Outlook, and Management Commentary
The filing does not contain forward-looking guidance, financial outlook, or management commentary regarding future operations. The primary communication is the announcement of the split's effectiveness and the appointment of Olde Monmouth Stock Transfer Co., Inc. as the exchange agent to manage the conversion of pre-split shares to post-split shares.
Investor Verification Checklist
- Verify the new share count and price per share on trading platforms effective May 5, 2017.
- Confirm receipt of the letter of transmittal from Olde Monmouth Stock Transfer Co., Inc. if holding physical certificates.
- Check with brokers for instructions regarding shares held in "street name."
- Review the attached Certificate of Amendment (Exhibit 3.1) for the official legal text of the capital structure change.